KIO 104
Alternative Names: KIO-104Latest Information Update: 27 Mar 2025
At a glance
- Originator Kiora Pharmaceuticals
- Class Anti-inflammatories; Eye disorder therapies; Small molecules
- Mechanism of Action Dihydroorotate dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Uveitis
- Preclinical Proliferative vitreoretinopathy
Most Recent Events
- 14 Feb 2025 Kiora Pharmaceuticals plans the phase II KLARITY-1 trial for Retinal oedema (Treatment-experienced) in Australia (Intravitreous, Injection), in April 2025 , (NCT06825702)
- 04 Sep 2024 Preclinical trials in Proliferative vitreoretinopathy in USA (Intravitreous) prior to September 2024 (Kiora Pharmaceuticals pipeline, September 2024)
- 21 Aug 2023 Kiora Pharmaceuticals anticipates to discuss the development path for KIO 104 in posterior non-infectious Uveitis with the US FDA in a type 2 pIND meeting in Q3 2024